BioTime

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

Mesoblast-stock

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner …

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »

Michael Cea ISSCR chat with Jeanne Loring on stem cell field

Lewy_Body_alphaSynuclein

By Michael Cea Jeanne Loring of the Scripps Research Institute in La Jolla, California kindly sat down with me at the ISSCR annual meeting for a broad discussion of her history, views on the field and developments in the science. I found Jeanne a refreshing character, as I did a number of others I was fortunate to …

Michael Cea ISSCR chat with Jeanne Loring on stem cell field Read More »

Tale of 7 stem cell biotech stock woes

Ocata

To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those …

Tale of 7 stem cell biotech stock woes Read More »

Rensselaer Polytechnic Institute stem cell meeting report

Mark-Noble

Last week I attended and spoke at a stem cell meeting at Rensselaer Polytechnic Institute (RPI). It was entitled, “Bioengineering and Stem Cell Research”. It was a great meeting with many interesting talks. Below I write about some of the talks and themes of the meeting. Still to come later this week I will do a second post entirely …

Rensselaer Polytechnic Institute stem cell meeting report Read More »

Advanced Cell Technology pub: Trial for Macular Degeneration

ACT-FIgure-1-

The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related …

Advanced Cell Technology pub: Trial for Macular Degeneration Read More »